Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism of diabetes.
Atherosclerosis is the principal cause of diabetic morbidity and mortality. Diabetic dyslipidemia, obesity, and hypertension are significant contributing factors in the acceleration of the atherosclerotic process. Regardless of the type of diabetes, increased levels of very-low-density lipoprotein triglyceride, modified levels of low-density lipoprotein cholesterol, and decreased levels of high-density lipoprotein (HDL) cholesterol are the main lipoprotein abnormalities in diabetic patients. These abnormalities can be improved in part by glycemic control, but additional intervention may be needed. Diet and exercise are important elements in the management of dyslipidemia, but lipid-lowering drugs (especially fibrates and HMG-CoA reductase inhibitors) also may be necessary for the control of diabetic dyslipidemia. Based on these findings, the American Diabetes Association Consensus Panel and the revised treatment guidelines of the National Cholesterol Education Program recommend treatment of hypertriglyceridemia/low HDL cholesterol as a risk factor of coronary heart disease in diabetic and nondiabetic individuals alike. Aggressive treatment is recommended, therefore, particularly in diabetic patients and in all patients with existing vascular disease.
Kim
D K
DK
Department of Medicine, Baylor College of Medicine, Methodist Hospital, Houston, Texas.
Escalante
D A
DA
Garber
A J
AJ
D001161:Arteriosclerosis / Q000517:prevention & control*; D003925:Diabetic Angiopathies / Q000097:blood / Q000517:prevention & control*; D004032:Diet; D015444:Exercise; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood* / Q000628:therapy; D006951:Hyperlipoproteinemias / Q000097:blood / Q000628:therapy; D015228:Hypertriglyceridemia / Q000097:blood / Q000628:therapy; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male
D000960:Hypolipidemic Agents